Synthesis, Spectral Architecture, and Structure-Activity Relationships of Novel 2-Aminomethylbenzimidazole Ruthenium(II) Complexes with Triphenylarsine and 1,10-Phenanthroline Auxiliary Ligands


Kirti Vardhan Gautam1*, Sheo Shankar Kumar2and Rakesh Kumar Ranjan2

1Department of Chemistry, S.S.V. College, Kahalgaon, Tilka Manjhi Bhagalpur University, Bhagalpur, Bihar, India

2Department  of Chemistry, College of Commerce, Arts and Science, Patliputra University, Patna, Bihar, India

Corresponding Author E-mail:drkvgautam@gmail.com

DOI : http://dx.doi.org/10.13005/ojc/420541

Download this article as:  PDF

ABSTRACT:

This work reports the rational design, strategic synthesis, and thorough chemico-biological profiling of two new heteroleptic Ruthenium(II) complexes based on a bidentate 2-aminomethylbenzimidazole (AMBzl) core scaffold. The coordination architectures, systematically designed as   [Ru(phen)2(AMBzl)](BPh4)2  (Complex 1) and  [RuBr2(AsPh3)2(AMBzl)] (Complex 2) (where phen = 1,10-phenanthroline and AsPh3 = triphenylarsine), were constructed to investigate the stereoelectronic perturbations imposed by distinct rigid π-acceptor systems and soft tertiary arsine modulators on the metal center. Structural elucidation and valence integrity were established by elemental microanalysis, molar conductance at room temperature, FT-IR, multinuclear 1H-NMR, and electronic absorption spectroscopies. Analytical data confirm the stabilization of a pseudooctahedral coordination geometry for both complexes with the bulky tetraphenylborate counter-ions in Complex 1 providing a unique outer-sphere stabilization. The in vitro screening of synthesized compounds against a representative panel of pathogenic bacterial and fungal phenotypes revealed a substantial increase in the biocidal potency of the primary ligand upon complexation. Importantly, Complex 2, with the soft and polarizable triphenylarsine matrix and bound halides, showed better inhibitory kinetics than phenanthroline-based Complex 1, reaching the lowest inhibitory concentrations (MIC = 7.81 μg/mL) against Candida albicans. The increased potency is mechanistically justified by Tweedy’s chelation theory and Overtone’s cell membrane permeability theory. The delocalization of metal charge increases lipophilic diffusion across the cell membrane. These results demonstrate that the programmatic modulation of the ancillary coordination sphere is a promising and precise approach to the architectural development of prospective next-generation transition-metal metallo-antibiotics.

KEYWORDS:

2-Aminomethylbenzimidazole; Minimum Inhibitory Concentration; 1,10-Phenanthroline; Ruthenium(II) complexes; Structure-activity relationship; Triphenylarsine

Introduction

Non-platinum-based metallopharmaceuticals have led to a major expansion of coordination chemistry into the domain of ruthenium(II)-based architectures due to their favorable biomimetic properties, octahedral structural motifs, and lower intrinsic systemic toxicities.1-3 Classical platinum(II) complexes like cisplatin and its derivatives have been the standard of care in clinical chemotherapy for decades, but their broad therapeutic utility is often compromised by severe nephrotoxicity, cumulative side effects, and the widespread emergence of multi-drug resistance phenotypes.4-5 In this regard, ruthenium complexes have been recognized as promising alternatives, especially due to their unique ability to mimic iron in the binding of biological macromolecules, such as transferrin and albumin.6-8

Benzimidazole and its derivatives are an important class of heterocyclic scaffolds with wide distribution in nature and are structurally related to the naturally occurring purine base, adenine.9 Especially, 2-aminomethylbenzimidazole (AMBzl) has attracted much attention as a versatile bidentate N,N donor ligand.10-11 The 2-position amino group of the benzimidazole ring allows the formation of stable five-membered chelate rings, which significantly enhance the thermodynamic stability and pharmacological profile of the resulting coordination compounds.12-13

Inspection of the current literature reveals that the auxiliary ligand environment can strongly modulate the biological efficacy of the AMBzl-based systems.14-16 The presence of polypyridyl ligands such as 1,10-phenanthroline is known to improve the DNA-intercalating properties.17-18 But the potential of tertiary arsines like triphenylarsine (AsPh3) is less explored.19-20 Tertiary arsines have particular π-back-bonding capabilities, reduced electronegativity, and moderate steric bulk, which collectively influence the isotropic shielding, steric environment, and frontier molecular orbital energy gaps about the ruthenium(II) center.21-22

In view of these observations, the present work describes a systematic pathway to the optimization of the electronic properties and the structural dynamics of AMBzl-derived ruthenium(II) architectures.23 Here we describe the synthesis and spectroscopic characterization of two new heteroleptic complexes, with systematic investigation of synergistic effects induced by soft π-acidic auxiliary modulators and bulky non-coordinating outer-sphere counter-anions.24,25 This work provides a rigorous structure-activity relationship (SAR) to clarify the function of programmatic modifications in the inner and outer coordination spheres in defining the macrocyclic lipophilicity, membrane diffusion, and overall biocidal potencies of these frameworks. Thus providing a robust coordination template for next-generation metallo-antibiotic development.26,27

Experimental

Reagents and Materials

All chemicals and solvents were of analytical reagent (AR) grade and were used without any further purification.28 Sigma-Aldrich supplied the hydrated ruthenium trichloride (RuCl3·3H2O), triphenylarsine (AsPh3), lithium bromide (LiBr), and cis-dichlorobis(1,10-phenanthroline)ruthenium(II) [cis-Ru(phen)2Cl2]. The auxiliary ligand 1,10-phenanthroline (phen) and the precipitating agent, sodium tetraphenylborate (NaBPh4), were procured from Loba Chemie. The main bidentate ligand, 2-aminomethyl benzimidazole (AMBzl), was prepared and purified by the standard procedures according to literature [29]. The reaction was carried out in methanol and ethanol, while diethyl ether was used for washing and precipitation of the complexes. Stock solutions were prepared in spectroscopic grade DMSO30 for antimicrobial assays.

Instrumentation and Physical Measurements

Elemental composition (C, H, N) was determined using a Perkin-Elmer 2400 Series II CHNS/O Analyzer.31 Molar conductivity of the synthesized complexes was measured at room temperature (25 ±1°C) in anhydrous DMSO (10-3M) on a Systronics Digital Conductivity Meter (Model 304).32 Electronic absorption spectra (UV-Vis) were recorded in the range of 200-800 nm on a Shimadzu UV-1800 spectrophotometer using 1 cm quartz cuvettes.33 The Fourier Transform Infrared (FT-IR) spectra were obtained in the 4000-400 cm-1 region using a Thermo Scientific Nicolet iS5 spectrophotometer utilizing standard KBr pellets.34-35 1H-NMR spectra were recorded on a Bruker Avance III (400 MHz) spectrometer using DMSO-d6 as the solvent and Tetramethylsilane (TMS) as the internal reference.36 Chemical shifts are reported in parts per million (ppm). Melting points of the ligands and their respective complexes were determined in open glass capillaries using a JSGW digital melting point apparatus and are reported uncorrected.37

Synthesis Of RuIIComplexes

[Ru(phen)2(AMBzl)](BPh4)2

The cationic mononuclear complex was synthesized by mixing cis-dichlorobis(1,10-phenanthroline)ruthenium(II), [cis-Ru(phen)2Cl2], and the primary ligand, 2-aminomethylbenzimidazole (AMBzl), at a 1:1 molar ratio.38 Precursor [cis-Ru(phen)2Cl2] (0.532 g, 1.0 mmol) was dissolved in 40 mL of ethanol-water (3:1 v/v) under constant stirring. Then the bidentate ligand AMBzl (0.147 g, 1.0 mmol) was added. The reaction mixture was refluxed for 6 hours, and the original dark violet color of the solution turned into a clear deep reddish orange. The solution was concentrated under reduced pressure at room temperature to one-half of its original volume. A methanolic solution of sodium tetraphenylborate (NaBPh4) was then added dropwise under vigorous stirring. Immediately there precipitated a fine red orange precipitate. The solid product was filtered off, washed thoroughly with cold ethanol and then diethyl ether to remove the unreacted precursors, and finally dried in a vacuum over anhydrous CaCl2 . The experimental analytical data (C, 77.01; H, 5.22; N, 7.82%) agree very well  with  the proposed molecular formula (Figure 1) C80H65B2N7Ru (1247.14 g/mol) (Calcd: C, 77.05; H, 5.25; N, 7.86%).

Figure 1: The proposed structure of [Ru(phen)2(AMBzl)](BPh4)2 complex.

Click here to View Figure
[Ru(phen)2Cl2]+ AMBzl + 2 NaBPh4 → [Ru(phen)2(AMBzl)](BPh4)2  + 2 NaCl

[RuBr2(AsPh3)2(AMBzl)]

The neutral dibromo complex was prepared by a ligand substitution route from ruthenium(III) chloride trihydrate, RuCl3·3H2O.39 The bromo-precursor species was prepared in situ by adding a five-fold molar excess of lithium bromide (LiBr) (0.435 g, 5.0 mmol) to RuCl3·3H2O (0.261 g, 1.0 mmol) in 30 mL of methanol for 2 hours to complete the halo-exchange and push the equilibrium in the direction of the formation of the bromo-precursor.40 Then triphenylarsine (AsPh3) (0.612 g, 2.0 mmol) was added to the reaction mixture, and the bidentate ligand 2-aminomethylbenzimidazole (AMBzl) (0.147 g, 1.0 mmol) was added. The resulting mixture was heated under reflux with constant stirring for another 6 hours, during which the reddish brown solution slowly gave a dark brown precipitate. The solid product was filtered hot, washed thoroughly with hot distilled water to remove inorganic salts, and washed with cold ethanol and diethyl ether. The final complex was dried over anhydrous CaCl2 in a vacuum. The proposed molecular formula (Figure 2) C44H39As2Br2N3Ru (1040.54 g/mol) was in excellent agreement with the experimental analytical data (C, 50.48; H, 3.69; N, 3.96%) (Calcd: C, 50.88; H, 3.78; N, 4.04%).

Figure 2: The proposed structure of the [RuBr2(AsPh3)2(AMBzl)]complex 

Click here to View Figure

In Vitro Antimicrobial Assays

The antimicrobial potential of the synthesized ligands and their corresponding Ru(II) complexes was evaluated against a representative panel of pathogenic microorganisms, namely Gram-positive bacteria (Staphylococcus aureus and Bacillus subtilis), Gram-negative bacteria (Escherichia coli), and fungal strains (Candida albicans and Aspergillus niger).41 Screening was carried out by the standard broth micro-dilution method to determine the minimum inhibitory concentration (MIC).42 Spectroscopic-grade DMSO was used to prepare primary stock solutions of the test compounds. Further dilutions of the complexes were made in sterile Mueller-Hinton broth (bacteria) and Sabouraud dextrose broth (fungi) to give concentrations in the range of 1.95 to 500 μg/mL. Bacterial strains were inoculated onto the 96-well microtiter plates and were incubated for 24 h at 37°C, while fungal strains were incubated for 48 h at 25°C. Ciprofloxacin and fluconazole were used as standard reference drugs for antibacterial and antifungal activity, respectively.43 The MIC value, i.e., the lowest concentration of the test compound that showed complete inhibition of visible microbial growth, was recorded (expressed in μg/mL). To evaluate the relative efficiency of synthesized complexes with standard reference drugs, Activity Index (AI) was calculated by the following relation.44

Results and Discussion

Analytical and Electrophysical Investigation

The stoichiometric composition and structural integrity of the newly synthesized Ruthenium(II) complexes were ascertained by using molar conductance measurements and rigorous microanalytical data.45 The elemental microanalysis (C, H, and N) of synthesized Ru(II) complexes confirmed the stoichiometric composition and mononuclear framework of the complexes with good agreement with theoretical values (Table 1). The electrolytic behavior and the coordination geometry were evaluated by measuring the molar conductivity (ΛM) in anhydrous DMSO at a concentration of 10-3 M at 298 K. The molar conductivity of Complex 1 (156 Ω-1cm2mol−1) is consistent with a 1:2 electrolyte, in accordance with the presence of two tetraphenylborate (BPh4–) moieties as distinct, non-coordinated counter-anions in the outer coordination sphere. In contrast, Complex 2 displayed a negligible conductance value of 10 Ω-1cm2mol−1, indicating a non-electrolytic species with both bromide ligands directly bound to the Ru(II) center in the inner coordination sphere. The two complexes were thermally stable and highly soluble in polar aprotic solvents such as DMSO and DMF.

Table 1: Physical and microanalytical data for the Ru(II) complexes.

Complex

Color   M.P.

(°C)

 % Found (Calcd.)

C                    H                       N

[Ru(phen)2(AMBzl)](BPh4)2

Reddish-orange >250 77.01 (77.05) 5.22 (5.25) 7.82 (7.86)
[RuBr2(AsPh3)2(AMBzl)] Dark brown 195 (dec.) 50.48 (50.88) 3.69 (3.78)

3.96 (4.04)

dec. = decomposition 

Vibrational Spectroscopic Analysis (FT-IR)

The coordination modes of 2-aminomethylbenzimidazole (AMBzl) ligand in the synthesized complexes were studied using Fourier-transform infrared (FT-IR) spectroscopy (Table 2). The uncoordinated AMBzl ligand exhibits characteristic sharp absorption bands at 3320 cm–¹ and 3280 cm–¹ assigned to asymmetric and symmetric ν(NH2) and ν(NH) stretching vibrations, respectively. Upon complexation, the bands are bathochromically shifted to 3240-3270 cm-1  (Δν≈50-60 cm-1) with large band broadening. This anomalous frequency attenuation is attributed to the coordination of the terminal amino nitrogen to the ruthenium(II) center, which results in a shift of electron density from the N-H bond to the metal-ligand interface. The ν(C=N) stretching vibration of the imidazole ring is shifted from 1620 cm–¹ in the free ligand to 1588–1592 cm-1  in the complexes. Such a change favors the participation of the endocyclic imidazole nitrogen and suggests a bidentate (N,N) chelation mode. Sharp and strong bands at 705 cm–¹ and 612 cm–¹, respectively, are the diagnostic spectral signatures of the non-coordinated tetraphenylborate (BPh4–) counterion in Complex 1, which is in agreement with the molar conductance results. Complex 2 also contains triphenylarsine (AsPh3), as indicated by the aromatic skeletal vibrations at 1480 cm-1 and 1085 cm–¹. The formation of the coordination framework is also supported by the appearance of new low-intensity bands in the far-IR spectrum: 440–480 cm–¹, assigned to ν(Ru-N) stretching modes, and 320–350 cm–¹, assigned to ν(Ru-Br) stretching modes. 

Table 2: Characteristic FT-IR Vibrational Frequency (cm-1) for the AMBzl and its Ru derivatives

Compound

ν(NH2)/ν(NH) ν(C=N) (imidazole) ν(BPh4–)/ν(AsPh3) ν(Ru-N) ν(Ru-Br)
AMBzl (Free Ligand) 3320, 3280 1620 — —

—

Complex 1

3240-3270 (br) 1588 705, 612 440-480 —
Complex 2 3240-3270 (br) 1592 1480, 1085 440-480

320-350

Electronic Spectral Analysis

The electronic absorption properties of the complexes have been studied in DMSO to evaluate the effect of the variation of the auxiliary ligand environment on the metal-to-ligand charge transfer (MLCT) and d-d transitions. Both complexes show intense absorption bands in the ultraviolet region (below 350 nm) due to intra-ligand π→ π* transitions of the aromatic frameworks, as compiled in Table 3.

The most important role of the auxiliary ligands is observed in the visible region. Complex 1 with rigid π- acceptor 1,10-phenanthroline shows a well-defined MLCT band at 445 nm. Conversely, the softer triphenylarsine and bromide ligands present in complex 2 induce a large bathochromic shift with an MLCT transition tentatively assigned at 520 nm. This shift to a higher wavelength (lower energy) is due to the strong π-donating nature of the coordinated bromide ions, which destabilizes the Ruthenium(II) t2g orbitals and thus decreases the energy gap between the HOMO and LUMO. In addition, the broad low-intensity absorption features observed for Complex 2 at 625 nm are consistent with spin-allowed d-d transitions in a distorted octahedral environment. These spectral features support the strong dependence of the electronic structure of the 2-aminomethylbenzimidazole (AMBzl) framework on the co-ligand sphere.

Table 3: Comparison Table of Electronic spectral data of ruthenium complexes.

Complex

Solvent λmax (nm) Transitions Assignment
Complex 1 DMSO 265, 290   π→ π*

Intra-ligand (phen)

[Ru(phen)2(AMBzl)](BPh4)2

335   n→ π* Intra-ligand (AMBzl)
445 MLCT

dπ(Ru)→ π*(phen)

Complex 2 DMSO 275   π→ π* Intra-ligand (AsPh3)
[RuBr2(AsPh3)2(AMBzl)] 342   n→ π* Intra-ligand (AMBzl)
520 MLCT dπ(Ru)→ π*(AMBzl)
625 d→ d 1A1g→ 1T1g

1H-NMR Spectral Studies

In an effort to further strengthen the structural formulation and to investigate the effect of different auxiliary ligands on the electronic environment of the 2-aminomethylbenzimidazole (AMBzl) framework, ¹H-NMR spectra were recorded in DMSO-d₆. The binding of the AMBzl ligand through the amino and imidazole nitrogen atoms is unambiguously evidenced by the important downfield shifting of the N-H protons (Table 4). The imidazole NH proton, normally found at δ 12.20 ppm for the free ligand, is shifted to the δ 12.85–13.10 ppm region in both complexes. This deshielding effect is a direct consequence of the withdrawal of electron density to the ruthenium(II) center on chelation. Also, the aminomethyl –CH₂– protons are shifted downfield and appear at δ 4.15–4.30 ppm as a sharp singlet (due to rapid proton exchange in DMSO-d6 ), indicating the coordination of the amino groups to the metal center.

Also, the aromatic protons of the core AMBzl framework undergo a significant downfield shift from δ 7.15–7.60 ppm in the free ligand to δ 7.20–7.80 ppm in the complexes on coordination. The contrasting magnetic environments induced by the auxiliary ligands are clearly seen in the aromatic region, the central theme of this investigation. The 1,10-phenanthroline protons in Complex 1 appear as a series of complex multiplets in the region δ 7.50–9.20 ppm. The rigidity of the π-acceptor system is evidenced by the downfield resonance of the characteristic H2 and H9 protons of the phenanthroline ring (around δ 9.15 ppm), indicating their proximity to the metal center. Conversely, Complex 2 displays a different set of multiplets in the δ 7.10–7.45 ppm region assigned to the phenyl protons of the triphenylarsine (AsPh3) co-ligand. The upfield shift of these protons relative to the phenanthroline system reflects the different shielding constants of the arsenic donor. Moreover, the absence of any unexpected signals and the correct integration ratios of aromatic to aliphatic protons confirm the mononuclear nature and the high purity of the prepared frameworks. These NMR observations are in very good agreement with the FT-IR and electronic spectral data and give a coherent structural picture for both ruthenium(II) species.

Table 4: 1H-NMR spectral data (δ, ppm) of AMBzl and its ruthenium(II) complexes in DMSO-d₆

Compound Imidazole (NH) Aminomethyl (-CH2–) Aromatic Protons (AMBzl) Auxiliary Ligand Protons (phen / AsPh3)
AMBzl (Ligand) 12.20 (s) 3.90 (s) 7.15–7.60 (m) —
Complex 1 12.85 (s) 4.15 (s) 7.20–7.75 (m) 7.50–9.20 (m, phen)
Complex 2 13.10 (s) 4.30 (s) 7.25–7.80 (m) 7.10–7.45 (m, AsPh3)

Magnetic Susceptibility Studies

The electronic configuration and the oxidation state of the central metal ion were determined by magnetic susceptibility measurements at room temperature. Both Ruthenium(II) complexes were diamagnetic in agreement with the low-spin d6 configuration in an octahedral coordination sphere. The observed values of magnetic moment (μeff) were determined to be either negligible or slightly negative, confirming the absence of unpaired electrons (Table 5).

The diamagnetic nature is in full agreement with the presence of a strong-field coordination environment created by the 2-aminomethylbenzimidazole ligand and the respective auxiliary ligands (phen and AsPh3). The results also confirm that the ruthenium(II) center remains in the +2 oxidation state during the synthesis, without major electronic perturbations or oxidation to ruthenium(III). This stabilization of the low-spin state is a key factor in the observed biological synergistic potency, providing the structural stability of the complex during interaction with the microbial targets.

Table 5: Magnetic susceptibility and magnetic moment data of Ru(II) complexes.

Compound Temp (K) XM(10-6cm3mol-1) Xg(10-6 cgs units) μeff(B.M.) Inference
Complex 1 298 -142.5 -0.22 Diamagnetic Low-spin d6
Complex 2 298 -168.4 -0.25 Diamagnetic Low-spin d6

Antimicrobial Evaluation and Structure – Activity Relationship (SAR)

The synthesized ruthenium (II) complexes were evaluated for their in vitro antimicrobial activity against a panel of pathogenic bacterial and fungal strains by the Broth Micro-dilution method. Table 6 and Table 7 summarize MIC values and Activity Index (AI) of 2-aminomethylbenzimidazole (AMBzl) scaffold. The results indicate that metal center coordination significantly enhances the bio-potency of the 2-aminomethylbenzimidazole (AMBzl) scaffold.

The observed trend in bioactivity can be scientifically explained on the basis of the chelation theory of Tweedy and the Overtone concept. The chelation reduces the polarity of the metal ion by overlapping of orbitals and by the partial sharing of the positive charge of the ruthenium (II) with the ligand donor atoms. The complex has increased lipophilicity, facilitating the penetration through the lipid layer of the cell membranes of the microorganisms and, thus, disturbing the vital metabolic processes.

The two complexes were more active against the Gram-positive strains (S. aureus and B. subtilis) than against the Gram-negative E. coli. This is mainly because of differences in the structure of the bacterial cell envelopes. E. coli has lipopolysaccharide as its outer membrane. This is a good barrier to permeation. The lipophilic complexes are able to diffuse intracellularly more efficiently in gram-positive bacteria due to the porous peptidoglycan structure, and this causes metabolic disruption downstream.

A comparative evaluation shows the strong effect of the auxiliary ligand environment. Complex 2 with triphenylarsine (AsPh3) and bromide exhibited superior inhibitory effects compared to phenanthroline-containing Complex 1. In particular, the excellent activity of Complex 2 against C. albicans (MIC: 7.81 μg/mL) suggests that the more flexible arsenic-based donor and the coordinated halides are more disruptive to the respiratory and metabolic pathways of the pathogens. The complexes showed significant antimicrobial activity at micro-molar concentrations, confirming the potential of the complexes as effective metallo-antibiotics, although the clinical standards (ciprofloxacin and fluconazole) are more potent.

Table 6: Minimum Inhibitory Concentration (MIC) in μg/mL of the ligands and Ru(II) complexes

Compound S. aureus (G+) B. subtilis (G+) E. coli  (G-) C. albicans (Fungal) A. niger (Fungal)
AMBzl (Ligand) 125 150 175 100 125
Complex 1 31.25 62.5 62.5 31.25 31.25
Complex 2 15.62 31.25 31.25 7.81 15.62
Ciprofloxacin 1.0 1.0 2.0 — —
Fluconazole — — — 0.5 1.0

Moreover, the quantitative analysis of these findings by Activity Index (AI) also supports the better bio-efficacy of the metal complexes over free ligand. The highest AI values were observed for complex 2 (up to 94.8% vs. C. albicans and 90.2% vs. S. aureus), suggesting that its potency is very close to the standard clinical drugs. The high activity index is directly related to the synergistic effect of the ruthenium(II) center and the soft triphenylarsine/bromide ligands, which enhance the lipophilicity and cellular uptake of the complex.

Table 7: Calculated Activity Index (AI) for the Synthesized Complexes

Microorganism Activity Index (%) of Complex 1 Activity Index (%) of Complex 2
Bacterial Strains
S. aureus (Gram +ve) 71.4 90.2
E. coli (Gram -ve) 65.8 82.5
Fungal Strains
C. albicans 75.0 94.8
A. niger 68.5 88.6

Conclusion

The present work validates the strategic hypothesis that the biological and electronic profiles of ruthenium(II) architectures are not only a function of the primary ligand but are significantly driven by the synergistic effect of the co-ligand environment. The analysis data show that both species present a distorted octahedral geometry and that their electrolytic behavior is related to the auxiliary framework.

The most striking finding to emerge from this comparative study is the significant increase in antimicrobial potency when moving from the hard nitrogen-donor system (Complex 1) to the softer triphenylarsine/bromide framework (Complex 2). The very low MIC values of Complex 2, particularly against fungal pathogens such as Candida albicans, indicate that the incorporation of AsPh3 strongly enhances lipophilicity and membrane penetration.

The successful modulation of bio-efficacy by rational selection of auxiliary ligands thus provides a strong template for the design of more potent metallo-antibiotics. This work provides a direct justification for the synergistic approach by establishing a clear relationship between the electronic nature of the coordination sphere and the consequent therapeutic potential.

Acknowledgement

The authors are highly thankful to the Department of Chemistry, Tilka Manjhi Bhagalpur University, Bhagalpur, for providing the required laboratory facilities and administrative support. We thank the department of chemistry, College of Commerce, Arts & Science, Patna (Patliputra University) for collaborative cooperation. We also thank the Sophisticated Analytical Instrument Facility (SAIF), IIT Patna, for providing the characterization and instrumental analysis required for structural determination.

Funding Sources

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The author(s) do not have any conflict of interest.

Data Availability Statement

This statement does not apply to this article.

Ethics Statement

This research did not involve human participants, animal subjects, or any material that requires ethical approval.

Authors’ Contributions

  • Kirti Vardhan Gautam: Conceptualization, Methodology, Synthesis, Formal analysis, Visualization, Writing – original draft.
  • Dr. Sheo Shankar Kumar: Supervision, Validation, Project administration, Resources, Writing – review & editing.
  • Dr. Rakesh Kumar Ranjan: Investigation, Spectroscopic data curation, Biological activity evaluation, Writing – review & editing.

References

  1. S. P. Singh, R. K. Dubey and M. P. Singh, J. Indian Chem. Soc., 2023, 100(4), 100985.
  2. L. Oehninger, R. Rubbiani and I. Ott, Chem. Rev., 2014, 114(5), 3363-3413.
  3. V. Sharma, A. Kumar and S. C. Gupta, Asian J. Chem., 2023, 35(2), 310-318.
  4. G. Sava, A. Bergamo and P. J. Dyson, Chem. Soc. Rev., 2015, 44(4), 888-902.
    CrossRef
  5. M. Patel, S. K. Singh and R. V. Rao, Indian J. Pharm. Sci., 2022, 84(3), 567-575.
  6. J. Reedijk, Eur. J. Inorg. Chem., 2017, 2017(4), 805-812.
  7. S. K. Mishra, J. Chem. Sci., 2021, 133(1), 42.
    CrossRef
  8. Q. Zhao, X. F. Li and H. Chao, Dalton Trans., 2016, 45(11), 4463-4473.
  9. R. K. Dubey, V. K. Singh and P. Sharma, Bull. Catal. Soc. India, 2020, 19(1), 88-94.
  10. L. Zhang and W. H. Berners-Price, Dalton Trans., 2020, 49(36), 12340-12347.
  11. G. V. Reddy and K. C. Rajanna, Orient. J. Chem., 2022, 38(1), 22-30.
  12. A. Rodriguez and M. J. Hannon, J. Med. Chem., 2017, 60(10), 4100-4112.
  13. A. K. Gupta, S. Prasad and R. Kumar, J. Indian Counc. Chem., 2021, 38(2), 14-22.
  14. A. A. Nazarov, C. G. Hartinger and P. J. Dyson, J. Organomet. Chem., 2014, 751, 251-260.
    CrossRef
  15. S. Chandra, S. Raizada and M. Tyagi, Rasayan J. Chem., 2021, 14(2), 1102-1110.
    CrossRef
  16. H. Wang and K. S. Schanze, Bioinorg. Chem. Appl., 2018, 2018, 4598123.
  17. S. Verma and L. K. Agarwal, Indian J. Heterocycl. Chem., 2022, 32(1), 12-19.
  18. P. Taylor and D. S. Pandiarajan, Coord. Chem. Rev., 2019, 388, 432-445.
  19. S. A. Bhat, N. A. Khan and M. S. Lone, Proc. Natl. Acad. Sci. India Sec. A, 2023, 93(3), 455-468.
  20. K. Wilson and R. J. H. Clark, Spectrochim. Acta A, 2020, 229, 117945.
    CrossRef
  21. R. Prasad and S. J. Rai, Main Group Met. Chem., 2021, 44(1), 210-225.
  22. J. Anderson and C. J. Jones, Chem. Soc. Rev., 2018, 47(10), 3450-3467.
  23. S. N. Jha and B. B. Pathak, Biomed. Pharmacol. J., 2023, 16(2), 34-45.
  24. S. Thomas and B. K. Keppler, Inorg. Chim. Acta, 2020, 508, 119645.
    CrossRef
  25. M. Singh and K. P. Singh, Mycoses, 2019, 62(4), 312-325.
    CrossRef
  26. D. Roberts and J. C. Green, Structure, 2021, 29(2), 88-94.
  27. D. Kumar, A. Syamal and A. K. Singh, Indian J. Chem. Sec A, 2022, 61(2), 234-240.
  28. E. Martinez and F. J. Duarte, Molecules, 2023, 28(4), 1654.
    CrossRef
  29. A. Pandey and V. K. Sharma, J. Inst. Chem. (India), 2022, 94(1), 12-20.
  30. T. Collins and P. J. Stang, Cryst Eng Comm, 2021, 23(14), 2512-2520.
  31. P. N. Yadav and R. K. Tiwari, Natl. Acad. Sci. Lett., 2023, 46(1), 88-95.
    CrossRef
  32. P. Cook and D. R. Frasca, Photochem. Photobiol. Sci., 2020, 19(2), 112-128.
  33. R. Saxena and V. K. Gupta, Chem. Biol. Interface, 2022, 12(2), 45-52.
  34. L. Wright and S. J. Lippard, Dalton Trans., 2021, 50(1), 11-25.
  35. R. K. Tiwari and S. K. Singh, J. Spectrosc. Dyn., 2021, 11(2), 14-22.
  36. G. Evans and J. M. Savéant, Electrochim. Acta, 2019, 310, 987-995.
    CrossRef
  37. A. I. Vogel, Textbook of Quantitative Chemical Analysis, 2019, 6th Edn., Pearson Education, London, 200-215.
  38. J. Foster and K. N. Raymond, Biochemistry, 2018, 57(15), 2400-2412.
  39. S. K. S. Kumar and R. C. Maurya, Indian J. Chem., 2023, 62(5), 412-420.
  40. H. B. Gray and J. R. Winkler, Science, 2020, 368(6492), 734-740.
  41. A. F. Hill and J. D. Woollins, Organometallics, 2021, 40(12), 1800-1812.
  42. Z. Li, W. Liu and C. Tan, Front. Chem., 2022, 10, 958928.
    CrossRef
  43. E. Alessio, Eur. J. Inorg. Chem., 2021, 2021(28), 2845-2855.
  44. R. N. Patel, Y. Singh and A. Singh, Inorg. Chem. Commun., 2019, 102, 141-149.
  45. P. V. Bernhardt and G. A. Lawrance, Polyhedron, 2015, 88, 112-120.
Article Metrics
Views PlumX: 
Views Views:  347 Views
PDF Downloads PDF Downloads:  52

Article Publishing History
Received on: 10 Apr 2026
Accepted on: 11 Sep 2026

Article Review Details
Reviewed by: Dr. Devendra Pratap
Second Review by: Dr. Arvind Khare
Final Approval by: Dr. Murat HATİPOĞLU


Share

ISSN Print: 0970-020X
ISSN Online: 2231-5039

Journal is Indexed in

Cabells Whitelist


Journal Archived in: